Bench to Bedside

The University of Kansas Cancer Center
Bench to Bedside

The University of Kansas Cancer Center’s podcast Bench to Bedside provides a glimpse into the latest research discoveries that are transforming cancer care. Join Roy Jensen, MD, vice chancellor and director of the cancer center, weekly to hear from the top experts in the field as well as patients and caregivers.

  1. 10 HR. AGO

    MyeloMATCH: The New Front in the Battle Against Leukemia

    In this episode of the Bench to Bedside Podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses exciting advancements in the treatment of acute myeloid leukemia (AML) with Dr. Tara Lin, director of the adult leukemia program at KU Cancer Center and site principal investigator for myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice), a precision-medicine initiative sponsored by the National Cancer Institute (NCI). MyeloMATCH is an “umbrella trial,” a group of clinical substudies for people with acute myeloid leukemia or myelodysplastic syndrome. In this conversation Dr. Lin explains the challenges of AML, as well as the innovative aspects of the myeloMATCH trial, such as rapid diagnostic testing and specialized clinical trial options based on genetic and molecular features. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the myeloMATCH trial View the myleoMATCH trial on the NCI’s clinical trials database Learn more about AML Read about clinical trials at KU Cancer Center Learn more about Dr. Tara Lin

    17 min
  2. NOV 27

    Strength in Love: Navigating the Journey as a Cancer Caregiver

    In this poignant episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Cheryl Jernigan, Lead Patient Research Advocate with Patient and Investigator Voices Organizing Together (PIVOT). Cheryl shares her powerful story of being both a cancer survivor herself and a co-survivor and caregiver to her husband, who battled both prostate cancer and tonsil cancer caused by human papillomavirus (HPV). Their discussion explores the emotional and physical challenges of caregiving, the importance of research and patient advocacy, and the vital support systems needed for caregivers. Cheryl's experience offers invaluable insight into balancing personal health while providing care, highlighting resources such as Turning Point and Gilda's Club to aid caregivers on their journey. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about KU Cancer Center’s patient research advocacy program, PIVOT Read Cheryl’s blog post about PIVOT on the KU Cancer Center website Find cancer caregiver resources at KU Cancer Center Learn more about Turning Point's services for cancer patients and caregivers at KU Cancer Center

    24 min
  3. NOV 6

    Investigating the Link Between Obesity and Cancer

    Being overweight or having obesity is linked with a higher risk of getting 13 types of cancer. These cancers comprise 40% of all cancers diagnosed in the United States each year. In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. John Thyfault, professor in the Department of Cell Biology and Physiology and in the Division of Endocrinology, Metabolism and Genetics, as well as director of the University of Kansas Diabetes Institute and co-leader of the Kansas Center for Metabolism and Obesity Research (KC-MORE), a new research hub based at the University of Kansas Medical Center to study human obesity and obesity-related disease. They discuss the significant impact of obesity on cancer incidence and mortality, as well as Dr. Thyfault’s work developing translational research to improve patient outcomes. The discussion also explores how hormonal disruptions caused by obesity affect tumor growth, the potential of pharmacologic interventions like Ozempic, and the importance of maintaining physical activity and a healthy diet in cancer prevention and management. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about KC-MORE Read about KC-MORE’s research into obesity and cancer Learn more about Dr. Thyfault

    19 min
  4. OCT 23

    Empowering the Future Leaders of Clinical Research with KU Cancer Center’s C-CLEAR Program

    In this episode of the Bench to Bedside podcast Joseph Hines, II, MPH, senior director of research operations at The University of Kansas Cancer Center, joins Dr. Roy Jensen, vice chancellor and director, to discuss the launch and success of the CAREERS in CLINICAL RESEARCH PROGRAM (C-CLEAR Program). This groundbreaking initiative is designed to introduce college students in the region to the dynamic and impactful field of clinical research. Hines, along with students Mariah Slaughter, Hilary Tallman, and Angel Tchamnou, share their experiences and the program's impact on their understanding of clinical research and oncology. The conversation covers the program's objectives, the challenges of its inception, as well as the achievements of its first cohort. The students also offer advice for future participants and express gratitude towards their mentors. Future developments and application details for the program are also highlighted. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the C-CLEAR Program Watch “A Day in the Life” with the C-CLEAR student interns Learn more about high school and undergraduate programs at KU Cancer Center

    20 min
  5. OCT 9

    Brain Health and Cancer: Addressing Cancer Related Cognitive Changes

    In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer center, speaks with Dr. Jamie Myers, an advanced practice oncology nurse with more than 40 years of experience and Research Associate Professor at the University of Kansas Medical Center’s School of Nursing. Dr. Myers’ research is focused on cognitive changes related to cancer and cancer treatment therapy. In this conversation, she shares more about this topic - often referred to as “chemo brain” – and how these cognitive changes affect memory, concentration and daily activities. Dr. Myers’ shares insights into her research on interventions to manage these cognitive changes and emphasizes the importance of physical activity and diet in aiding brain health, as well as offering resources for listeners wanting to learn more.   Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode:  Learn more about Dr. Myers  Read “Lifting the Fog on Chemobrain” by Dr. Myers on the KU Cancer Center blog Watch Dr. Myers’ talk more about her research and nursing background

    17 min
  6. MAY 22

    Exploring the Future of Cancer Care: What is Tumor-Infiltrating Lymphocyte (TIL) Therapy?

    Immunotherapy and cellular therapeutics represent the future of cancer care. These biological therapies involve manipulating the body’s cells to reactivate and strengthen their abilities to attack cancer cells. Immunotherapy is a precision cancer treatment and is considered the future of cancer treatment by the National Cancer Institute. Other, more traditional, types of cancer treatment include surgery, chemotherapy and radiation. Immunotherapy is a type of treatment for a variety of cancers that harnesses one’s own immune system to fight his or her specific cancer cells. Tumor infiltrating lymphocyte, or TIL therapy, is a type of immunotherapy and part of the body’s natural response to cancer. TIL cells are naturally occurring immune cells that are on constant surveillance to recognize, attack and kill cancer cells. Recently, the Food and Drug Administration approved lifileucel (Amtagvi), the first treatment for cancer that uses TILs. On this episode, Dr. Roy Jensen, vice chancellor and director of KU Cancer Center speaks with Dr. Muhammad Mushtaq, associate professor of hematologic malignancies and cellular therapeutics at the University of Kansas Medical Center, about this exciting topic. Links from this Episode: Learn more about TIL therapy via the National Cancer Institute Read the frequently asked questions about immunotherapy on the KU Cancer Center website Learn about Dr. Mushtaq Read the FDA’s announcement of approval for TIL therapy Learn more about cancer clinical trials at KU Cancer Center After listening to this episode, we invite YOU to be a part of the podcast! We want to hear your thoughts on the conversations we have here, topics you’d like to learn more about and any questions you may have for our guests. Call our Bench to Bedside hotline at 913-588-3880 and leave us a voicemail, or you can email your comments and questions to benchtobedside@kumc.edu. Your comments may be shared on a future episode!

    16 min

Ratings & Reviews

3.7
out of 5
3 Ratings

About

The University of Kansas Cancer Center’s podcast Bench to Bedside provides a glimpse into the latest research discoveries that are transforming cancer care. Join Roy Jensen, MD, vice chancellor and director of the cancer center, weekly to hear from the top experts in the field as well as patients and caregivers.

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada